Peptides for looksmaxxing: what the evidence actually shows

The verdict

SoftMaxx AI reviewed 74 entries (peptides, blends and peptide-adjacent compounds) and every paper we could verify on PubMed. We found no study of a peptide sold for looks that measured facial attractiveness, facial proportions or the jaw as an outcome. Growth-hormone therapy in children, a protein hormone rather than a looks peptide, has measured facial ratios and jaw growth, reported as preliminary trends ^[1]. The closest for looks peptides are topical trials that measured facial wrinkles ^[2][3].

So this page ranks peptides by how much human evidence exists, not by how good they are said to look. A high tier means more human evidence exists for some outcome. It never means a better face.

• Common beliefSemaglutide gives you a sharper faceNo supporting study We found no semaglutide trial that measured the face. The two pieces on "Ozempic face" cited here are commentary on facial volume loss after rapid weight loss.^[6][7]
• Common beliefMK-677 grows your jawNo supporting study We found no MK-677 trial that measured facial bones. A 2-year trial in adults aged 60 to 81 recorded transient, mild leg swelling (edema).^[8]

The tiers, by evidence

The sections below give the sources for each row.

• Human RCT In the STEP 1 trial, semaglutide produced about 15% weight loss versus 2.4% on placebo at 68 weeks.^[9]
• Expert review A 2025 meta-analysis of 23 collagen trials found no skin benefit in trials without industry funding or in high-quality trials.^[13]
• Human, small or uncontrolled FDA's July 2026 briefing lists five clinical studies of BPC-157, two of them placebo-controlled, all small and short. A 2025 systematic review counted 35 preclinical studies and 1 clinical study.^{[16][22][23][24][25]}
• Regulator document FDA's July 2026 briefing found no clinical studies or human exposure data for TB-500, including no human pharmacokinetic data.^[20]
• Regulator document FDA states it has not identified any human exposure data for KPV.^[21]

Injected "glow" and recovery peptides: almost no human data

Health Canada lists BPC-157, TB-500, KPV and GHK-Cu among unauthorized injectable peptides it has seized, and says such products are often promoted online, including for injury recovery and athletic performance ^[26].

Their human record runs from five small clinical studies (BPC-157) to no human exposure data at all (TB-500, KPV), per FDA ^{[16] [20] [21]}. FDA's briefing lists no human study of BPC-157 on skin ^[16]. One of the three FDA adverse-event reports for BPC-157, on a product that also contained TB-500, was a skin reaction ^[16]; FDA's TB-500 briefing notes two more reports on blended TB-500 and BPC-157 in its food and supplement system, with no safety assessment ^[20]. The full breakdown is on the GLOW and KLOW pages.

• Claim as marketedGLOW and KLOW are tested skin injectionsNo supporting study We found no published study of the GLOW or KLOW blends in people, animals or cells. For one of their ingredients, TB-500, FDA found no human exposure data.^[20]
• Case report One of the three FDA adverse-event reports for BPC-157 describes diffuse skin and gum darkening after a product that also contained TB-500. It came back when the person used it again.^[16]
• Animal In a controlled rat study of BPC-157 with TB-500 (32 rats, 8 per group), the pair gave no added benefit over either alone.^[27]

Melanotan II: the tanning peptide with documented harms

Melanotan II is unlicensed ^[28], and we found no FDA-approved product containing it in Drugs@FDA ^[29]. The earliest human study we found was a 1996 pilot in 3 men ^[17].

Since then, the reports we found are mostly case reports of harm ^{[18] [19] [30] [28]}. Vials sold illegally online held less drug than labelled, and vials from two of three shops held unknown impurities ^[31].

• Human, small or uncontrolled The phase I pilot of Melanotan II enrolled 3 healthy men; 2 of 3 showed more skin pigment.^[17]
• Case report Case reports describe new and darkening moles after Melanotan II, in one case within 24 hours of a single injection.^[18][19]
• Case report Melanomas have been reported in Melanotan II users. In one published case the woman also used sunbeds, so cause is not established.^[30][28]
• Common beliefA Melanotan tan protects your skinExpert review A 2025 review states that activating the melanin receptor may lower melanoma risk but does not stop melanoma, especially in people with risk factors.^[32]

MK-677, growth hormone and follistatin: the jaw myths

We found no trial showing that growth-hormone drugs give adults a bigger jaw.

In adults, jaw and facial bone growth from excess growth hormone is documented in acromegaly, a chronic disease whose signs progress slowly ^[33]. Claims about hard mewing deserve the same caution. In a lab analysis of 17 black-market "follistatin 344" products, only 9 contained follistatin ^[34]. The jawline page covers this in full.

• Human RCT In a 2-year trial in older adults, MK-677 raised lean mass by about 1.1 kg. It did not reduce body fat, and it raised fasting glucose.^[8]
• Human RCT A hip-fracture trial of MK-677 was stopped early for a heart-failure signal.^[5]
• Expert review Jaw (mandibular) overgrowth is reported in 22–24% of people with acromegaly, a disease of excess growth hormone. Thickened frontal bones and a protruding brow are among its common facial changes.^[33]

GLP-1 drugs and "Ozempic face"

Semaglutide and tirzepatide are FDA-approved drugs ^[35]: semaglutide as Ozempic for diabetes ^[6] and as Wegovy to reduce excess body weight ^[10]. Your prescriber sets your dose; the label is on DailyMed.

Rapid weight loss on semaglutide can deplete facial volume and fat ^[6]. We found no trial that tested the face directly. Hair loss is listed as a side effect on the Wegovy label ^[10].

• Common belief"Ozempic face" is a special effect of the drugExpert review Commentaries tie "Ozempic face" to rapid weight loss on the drug that depletes facial volume and fat. One asks whether it is a new drug effect or a natural result of rapid weight loss, and leaves that open.^[6][7]
• Drug label In the label's pooled adult weight-loss trials, hair loss was reported in 3.3% of people on Wegovy 2.4 mg versus 1% on placebo.^[10]

Oral collagen: pooled gains, funding questions

Oral collagen is a food supplement, not a drug. Meta-analyses have pooled 19 to 26 randomized skin trials of it ^[12][36].

The catch is who paid for them. In a 2025 meta-analysis, the benefit was absent in trials without pharmaceutical-company funding and in high-quality trials ^[13].

• Expert review Meta-analyses pooling many small trials report better skin hydration and elasticity with oral collagen.^[12][36]
• Human RCT In one trial of 114 women, a specific bioactive collagen peptide product reduced eye-wrinkle volume by about 20% over 8 weeks.^[37]
• Expert review A 2025 meta-analysis found no skin benefit in trials without pharmaceutical-company funding or in high-quality trials.^[13]

Topical peptides: small, short trials

Trials of peptide creams and serums measured fine lines and wrinkles over weeks, not face shape ^[2][3]. The skin guide ranks them one by one.

• Human RCT A 12-week split-face trial of palmitoyl pentapeptide (pal-KTTKS) in 93 women reported fewer fine lines than the same moisturizer without peptide.^[2]
• Human RCT Argireline results are mixed: positive in a 60-person trial and not significant in a 19-person split-face study. A 21-person trial found a palmitoyl pentapeptide-4 cream did better than an acetylhexapeptide-3 cream; its abstract does not state whether that is the same substance as argireline.^[3][4][38]
• Expert review Two reviews describe the human evidence for topical GHK-Cu as thin, with few clinical studies.^[14][15]

What you can measure instead

Published research can't tell you what your own face is doing. A repeatable measurement can.

The SoftMaxx AI scan scores your skin, jawline and other areas from a photo. If you start a topical routine, scan before you begin. Rescan every few weeks in the same light, at the same angle.

A photo score is not a lab instrument, and lighting moves it. Read small changes with caution. For the broader idea, see what softmaxxing is and looksmaxxing vs softmaxxing.

Doses used in studies (not a recommendation)

These are the amounts given to the people, animals or cells in the cited studies, copied as reported. They are a record of what was tested, not dosing instructions, and nothing here says what you should take.

Side effects and risks

• Case report Melanotan II: new and darkening moles in case reports; melanomas reported in users, and in one case the user also used sunbeds^{[18][19][30][28]}
• Case report Product with BPC-157 and TB-500: diffuse skin and gum darkening (one of three FDA adverse-event reports for BPC-157)^[16]
• Human RCT MK-677: higher fasting glucose, lower insulin sensitivity, fluid retention^[8]
• Human RCT MK-677: heart-failure signal that stopped a hip-fracture trial early^[5]
• Drug label Semaglutide (Wegovy 2.4 mg): hair loss, 3.3% vs 1% on placebo in pooled adult trials^[10]
• Regulator document Several injected unapproved peptides: FDA flags possible immune reactions linked to impurities or aggregation^[21]

Regulatory status (checked 2026-09-30)

• United States (FDA)Semaglutide is FDA-approved as Ozempic and Wegovy (prescription drugs). (DailyMed: OZEMPIC (semaglutide) injection — Prescribing Information; DailyMed: WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information) Tirzepatide is FDA-approved as Mounjaro and Zepbound (prescription drugs). (DailyMed: MOUNJARO (tirzepatide) injection — Prescribing Information; DailyMed: ZEPBOUND (tirzepatide) injection — Prescribing Information) We found no FDA-approved product containing ibutamoren (MK-677) in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: ibutamoren — no approved product found) FDA lists Ibutamoren mesylate (MK-677) in 503A Category 2, “Bulk Drug Substances that Raise Significant Safety Risks”, added 2023-09-29. (FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act; FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks) We found no FDA-approved product containing BPC-157 in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: bpc-157 — no approved product found) FDA removed BPC-157 from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act; FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks) We found no FDA-approved product containing TB-500 in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: tb-500 — no approved product found) FDA removed Thymosin beta-4 fragment (LKKTETQ), 'TB-500' from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act; FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks) We found no FDA-approved product containing KPV in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: kpv — no approved product found) FDA removed KPV from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act; FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks) We found no FDA-approved product containing Melanotan II in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: melanotan-ii — no approved product found) FDA removed Melanotan II from 503A Category 2 on 2026-04-22 after the nominations were withdrawn; FDA’s safety page still lists it under “Bulk drug substances nominated but withdrawn”. (FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act; FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks) We found no FDA-approved product containing GHK-Cu in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: ghk-cu — no approved product found) FDA lists GHK-Cu (except for injectable routes of administration) in 503A Category 1, “Bulk Drug Substances Under Evaluation” (list updated 2026-05-14). (FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act) In the US, dietary supplement firms are responsible for evaluating the safety and labeling of their products before marketing, and FDA can act against a product that is adulterated or misbranded after it reaches the market. (FDA: Dietary Supplements)
• CanadaOzempic and Wegovy (semaglutide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada: Health Canada Drug Product Database: OZEMPIC (semaglutide) — Drug Identification Numbers listed; Health Canada: Health Canada Drug Product Database: WEGOVY (semaglutide) — Drug Identification Numbers listed) Mounjaro and Zepbound (tirzepatide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada: Health Canada Drug Product Database: MOUNJARO (tirzepatide) — Drug Identification Numbers listed; Health Canada document) We found no product containing ibutamoren (MK-677) in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: ibutamoren — no product found) We found no product containing BPC-157 in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: bpc-157 — no product found) We found no product containing TB-500 in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: tb-500 — no product found) We found no product containing KPV in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: kpv — no product found) We found no product containing Melanotan II in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: melanotan-ii — no product found) We found no product containing GHK-Cu in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: ghk-cu — no product found) Health Canada named GHK-Cu in “Think twice before injecting peptides bought online: unauthorized products can seriously harm you”. (Health Canada: Think twice before injecting peptides bought online: unauthorized products can seriously harm you) Health Canada named GHK-Cu in “Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks”. (Health Canada document) Health Canada named GHK-Cu in “Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks”. (Health Canada document) Health Canada named GHK-Cu in “GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients”. (Health Canada document)
• Sport (WADA)Semaglutide is not on the 2026 WADA Prohibited List. (WADA: World Anti-Doping Code International Standard Prohibited List 2026) Tirzepatide is not on the 2026 WADA Prohibited List. (WADA: World Anti-Doping Code International Standard Prohibited List 2026) Ibutamoren (MK-677) is named on the 2026 WADA Prohibited List (S2.2.4). (WADA: World Anti-Doping Code International Standard Prohibited List 2026) BPC-157 is named on the 2026 WADA Prohibited List (S0). (WADA: World Anti-Doping Code International Standard Prohibited List 2026) TB-500 is named on the 2026 WADA Prohibited List (S2.3). (WADA: World Anti-Doping Code International Standard Prohibited List 2026) KPV is not named on the 2026 WADA Prohibited List; by our reading it falls under S0, non-approved substances. (WADA: World Anti-Doping Code International Standard Prohibited List 2026) Melanotan II is not named on the 2026 WADA Prohibited List; by our reading it falls under S0, non-approved substances. (WADA: World Anti-Doping Code International Standard Prohibited List 2026) WADA’s Prohibited List does not name GHK-Cu. WADA states that topical cosmetic products may contain prohibited peptides or growth factors and that using cosmetic products containing such substances is prohibited; we found no WADA statement on whether GHK-Cu is one of them. (WADA: World Anti-Doping Code International Standard Prohibited List 2026; WADA: World Anti-Doping Agency Prohibited List) Collagen peptides are not on the 2026 WADA Prohibited List. (WADA: World Anti-Doping Code International Standard Prohibited List 2026)

Official sources: FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act · WADA: World Anti-Doping Code International Standard Prohibited List 2026

Report a side effect

Common questions

References

Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.

1. Effects of growth hormone therapy on facial anthropometric features in children with growth disorders: a cohort study. Ann Med Surg (Lond) (2026). PubMed 42583639 DOI
2. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci (2005). PubMed 18492182 DOI
3. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol (2013). PubMed 23417317 DOI
4. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol (2023). PubMed 36909866
5. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr (2011). PubMed 21067829 DOI
6. Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. Facial Plast Surg (2023). PubMed 37541662 DOI
7. Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. J Drugs Dermatol (2024). PubMed 38206146 DOI
8. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med (2008). PubMed 18981485 DOI
9. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). PubMed 33567185 DOI
10. WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information DailyMed (2026). Source
11. ZEPBOUND (tirzepatide) injection — Prescribing Information DailyMed (2026). Source
12. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol (2021). PubMed 33742704 DOI
13. Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Med (2025). PubMed 40324552 DOI
14. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts (2025). PubMed 39963574 DOI
15. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res (2026). PubMed 42787770 DOI
16. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate) (2026). Source
17. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci (1996). PubMed 8637402 DOI
18. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol (2009). PubMed 19575725 DOI
19. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol (2014). PubMed 24334249 DOI
20. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate) (2026). Source
21. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks fda.gov (2026). Source
22. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery (2025). PubMed 40756949 DOI
23. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine (2021). PubMed 34324435
24. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative therapies in health and medicine (2024). PubMed 39325560
25. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative therapies in health and medicine (2025). PubMed 40131143
26. Think twice before injecting peptides bought online: unauthorized products can seriously harm you (Health Canada advisory; lists KPV) Recalls and safety alerts, Government of Canada (2026). Source
27. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery (2026). PubMed 42542926 DOI
28. Melanoma associated with the use of melanotan-II. Dermatology (2014). PubMed 24355990 DOI
29. Drugs@FDA search: melanotan-ii — no approved product found (2026-10-01) Drugs@FDA (openFDA) (2026). Source
30. Melanotan-associated melanoma. Br J Dermatol (2011). PubMed 21564053 DOI
31. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal (2015). PubMed 24771717 DOI
32. An overview of benefits and risks of chronic melanocortin-1 receptor activation. J Eur Acad Dermatol Venereol (2025). PubMed 39082868 DOI
33. Oral Manifestations and Maxillo-Facial Features in the Acromegalic Patient: A Literature Review. J Clin Med (2022). PubMed 35207363 DOI
34. Detection of black market follistatin 344. Drug testing and analysis (2019). PubMed 31758732 DOI
35. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med (2026). PubMed 42757290
36. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis. Nutrients (2023). PubMed 37432180 DOI
37. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacol Physiol (2014). PubMed 24401291 DOI
38. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysis. GMS Interdiscip Plast Reconstr Surg DGPW (2023). PubMed 38024099 DOI
39. Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. J Agric Food Chem (2005). PubMed 16076145 DOI